MX2018003801A - Formulacion de hipericina para la terapia fotodinamica. - Google Patents
Formulacion de hipericina para la terapia fotodinamica.Info
- Publication number
- MX2018003801A MX2018003801A MX2018003801A MX2018003801A MX2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- hypericin
- photodynamic therapy
- polyvinylpyrrolidone
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una formulación que puede usarse como fotosensibilizador en la terapia del cáncer, por ejemplo cáncer de vejiga, contiene sal de hipericina sódica complejada con polivinilpirrolidona o con polivinilpirrolidona,.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT6302015 | 2015-09-28 | ||
PCT/AT2016/000033 WO2017054017A1 (de) | 2015-09-28 | 2016-04-07 | Formulierung von hypericin zur photodynamischen therapie |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003801A true MX2018003801A (es) | 2018-11-09 |
Family
ID=55854522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003801A MX2018003801A (es) | 2015-09-28 | 2016-04-07 | Formulacion de hipericina para la terapia fotodinamica. |
Country Status (14)
Country | Link |
---|---|
US (3) | US10143751B2 (es) |
EP (1) | EP3237010B1 (es) |
JP (1) | JP6800231B2 (es) |
KR (1) | KR102194523B1 (es) |
CN (1) | CN108348609A (es) |
AU (1) | AU2016331656B2 (es) |
BR (1) | BR112018006043B1 (es) |
CA (1) | CA3000409C (es) |
DK (1) | DK3237010T3 (es) |
ES (1) | ES2750818T3 (es) |
MX (1) | MX2018003801A (es) |
PL (1) | PL3237010T3 (es) |
RU (1) | RU2018114867A (es) |
WO (1) | WO2017054017A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9629932B2 (en) * | 2015-09-28 | 2017-04-25 | Sanochemia Pharmazeutika Ag | Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof |
EP3593815A1 (de) * | 2018-07-13 | 2020-01-15 | Planta Naturstoffe Vertriebsges.m.b.h. | Hypericin-pvp komplex mit hohem hypericinanteil |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814014A1 (de) | 1997-12-19 | 1999-09-30 | Krewel Meuselbach Gmbh | Arzneipflanzentrockenextrakte |
DE19756677A1 (de) | 1997-12-19 | 1999-06-24 | Krewel Meuselbach Gmbh | Arzneipflanzentrockenextrakte |
AT408835B8 (de) | 2000-05-23 | 2002-07-25 | Andreas Dipl Ing Dr Kubin | Präparation von hypericin gebunden an polyvinylpyrrolidon (pvp) verschiedenen polymerisations- und vernetzungsgrades |
CN101130082A (zh) * | 2007-07-27 | 2008-02-27 | 许川山 | 具有携氧功能的新型光敏剂 |
WO2009066294A1 (en) | 2007-11-20 | 2009-05-28 | Hy Biopharma Inc. | Device and method for photodynamic therapy |
CN104415348A (zh) * | 2013-08-27 | 2015-03-18 | 汪步海 | 一种放疗增敏剂及其制备方法 |
DE102014204138A1 (de) | 2014-03-06 | 2015-09-24 | Briu Gmbh | Pharmazeutische Formulierung, Verfahren zur Herstellung der pharmazeutischen Formulierung und Infusionslösung sowie deren Verwendung als Medizinprodukt und/oder als Medikament |
-
2015
- 2015-10-08 US US14/878,515 patent/US10143751B2/en active Active
-
2016
- 2016-04-07 JP JP2018535200A patent/JP6800231B2/ja active Active
- 2016-04-07 MX MX2018003801A patent/MX2018003801A/es unknown
- 2016-04-07 EP EP16718843.2A patent/EP3237010B1/de active Active
- 2016-04-07 RU RU2018114867A patent/RU2018114867A/ru not_active Application Discontinuation
- 2016-04-07 AU AU2016331656A patent/AU2016331656B2/en active Active
- 2016-04-07 CN CN201680064158.2A patent/CN108348609A/zh active Pending
- 2016-04-07 WO PCT/AT2016/000033 patent/WO2017054017A1/de active Application Filing
- 2016-04-07 BR BR112018006043-7A patent/BR112018006043B1/pt active IP Right Grant
- 2016-04-07 CA CA3000409A patent/CA3000409C/en active Active
- 2016-04-07 KR KR1020187012188A patent/KR102194523B1/ko active IP Right Grant
- 2016-04-07 DK DK16718843T patent/DK3237010T3/da active
- 2016-04-07 PL PL16718843T patent/PL3237010T3/pl unknown
- 2016-04-07 ES ES16718843T patent/ES2750818T3/es active Active
-
2017
- 2017-11-07 US US15/805,491 patent/US10265397B2/en active Active
- 2017-11-07 US US15/805,664 patent/US10201609B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2018114867A3 (es) | 2019-10-28 |
PL3237010T3 (pl) | 2020-03-31 |
CA3000409C (en) | 2021-05-25 |
US10265397B2 (en) | 2019-04-23 |
WO2017054017A1 (de) | 2017-04-06 |
KR102194523B1 (ko) | 2020-12-24 |
BR112018006043B1 (pt) | 2023-10-31 |
US20180055934A1 (en) | 2018-03-01 |
RU2018114867A (ru) | 2019-10-28 |
US10143751B2 (en) | 2018-12-04 |
AU2016331656A1 (en) | 2018-05-10 |
EP3237010A1 (de) | 2017-11-01 |
JP6800231B2 (ja) | 2020-12-16 |
US10201609B2 (en) | 2019-02-12 |
DK3237010T3 (da) | 2019-11-11 |
US20180055935A1 (en) | 2018-03-01 |
US20170087249A1 (en) | 2017-03-30 |
AU2016331656B2 (en) | 2019-07-04 |
CA3000409A1 (en) | 2017-04-06 |
EP3237010B1 (de) | 2019-08-14 |
KR20180068996A (ko) | 2018-06-22 |
CN108348609A (zh) | 2018-07-31 |
ES2750818T3 (es) | 2020-03-27 |
BR112018006043A2 (pt) | 2018-10-09 |
JP2018529768A (ja) | 2018-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290149A (en) | Combined treatment for cancer | |
EP3368656A4 (en) | TARGETED CANCER THERAPY | |
EP3651772A4 (en) | ANTI-CANCER POLYTHERAPY | |
EP4324473A3 (en) | Multiparametric nucleic acid optimization | |
EP3180010A4 (en) | Combination therapy for treating cancer | |
SI3423087T1 (sl) | Kombinirana terapija proti raku | |
EP3407978A4 (en) | COMBINATION THERAPY FOR TREATING CANCER | |
EP3307240A4 (en) | Combination therapy for the treatment of cancer | |
MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
EP3285773A4 (en) | POLY THERAPY FOR THE TREATMENT OF CANCER | |
EP3207162A4 (en) | Combination therapy for use in cancer therapy | |
EP3359192A4 (en) | POLY THERAPY FOR THE TREATMENT OF CANCER | |
EP3362066A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
EP3258965A4 (en) | Combination therapy for cancer treatment | |
HK1258319A1 (zh) | 癌症療法 | |
EP3193884A4 (en) | Combination therapy for treating cancer | |
EP3131552A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
EP3362065A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
EP3541818A4 (en) | PHOTOSENSITIZER | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
EP3256115A4 (en) | COMBINATION CANCER THERAPY | |
NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
BR112018012116A2 (pt) | terapia intravesical para câncer de bexiga | |
MX2018003802A (es) | Formulacion de hipericina para el diagnostico fotodinamico. | |
EP3675891A4 (en) | ANTI-CANCER POLYTHERAPY |